Zhu, Jun <br/><br/>
Cost-effectiveness of afatinib and erlotinib as second-line treatments for advanced squamous cell carcinoma of the lung.  [electronic resource] 

 -  Future oncology (London, England)  Nov 2018 
 - 2833-2840 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article 
<br/><br/><label>ISSN: </label>1744-8301 
<br/><br/><label>Standard No.: </label>10.2217/fon-2018-0321  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Afatinib--economics<br/>Antineoplastic Agents--economics<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Carcinoma, Squamous Cell--drug therapy<br/>China<br/>Clinical Decision-Making<br/>Cost-Benefit Analysis<br/>Decision Support Techniques<br/>Erlotinib Hydrochloride--economics<br/>Humans<br/>Lung Neoplasms--drug therapy<br/>Models, Economic<br/>Progression-Free Survival<br/>Quality-Adjusted Life Years